Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):230–233. doi: 10.1128/aac.40.1.230

Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.

E Cañas 1, J Pachon 1, F Garcia-Pesquera 1, J R Castillo 1, P Viciana 1, J M Cisneros 1, M E Jimenez-Mejias 1
PMCID: PMC163089  PMID: 8787912

Abstract

Pharmacokinetic parameters of zidovudine (ZDV) were not altered in 16 patients receiving concomitant therapy with ZDV and trimethoprim-sulfamethoxazole by oral administration. ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively. ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.

Full Text

The Full Text of this article is available as a PDF (178.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blum M. R., Liao S. H., Good S. S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988 Aug 29;85(2A):189–194. [PubMed] [Google Scholar]
  2. Burger D. M., Meenhorst P. L., Koks C. H., Beijnen J. H. Drug interactions with zidovudine. AIDS. 1993 Apr;7(4):445–460. doi: 10.1097/00002030-199304000-00001. [DOI] [PubMed] [Google Scholar]
  3. Chatton J. Y., Munafo A., Chave J. P., Steinhäuslin F., Roch-Ramel F., Glauser M. P., Biollaz J. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol. 1992 Dec;34(6):551–554. [PMC free article] [PubMed] [Google Scholar]
  4. Collins J. M., Unadkat J. D. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989 Jul;17(1):1–9. doi: 10.2165/00003088-198917010-00001. [DOI] [PubMed] [Google Scholar]
  5. Feinberg J., Leport C., Reiss P. Update on opportunistic infections. AIDS. 1991;5 (Suppl 2):S195–S202. [PubMed] [Google Scholar]
  6. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  8. Langtry H. D., Campoli-Richards D. M. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Apr;37(4):408–450. doi: 10.2165/00003495-198937040-00003. [DOI] [PubMed] [Google Scholar]
  9. Laskin O. L., de Miranda P., Blum M. R. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis. 1989 Apr;159(4):745–747. doi: 10.1093/infdis/159.4.745. [DOI] [PubMed] [Google Scholar]
  10. Macleod R., Eagling V. A., Sim S. M., Back D. J. In vitro inhibition studies of the glucuronidation of 3'-azido-3'-deoxythymidine catalysed by human liver UDP-glucuronosyl transferase. Biochem Pharmacol. 1992 Jan 22;43(2):382–386. doi: 10.1016/0006-2952(92)90303-z. [DOI] [PubMed] [Google Scholar]
  11. Martin M. A., Cox P. H., Beck K., Styer C. M., Beall G. N. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med. 1992 Mar;152(3):523–528. [PubMed] [Google Scholar]
  12. Maxwell S. Endocarditis due to Streptococcus morbillorum. J Infect. 1989 Jan;18(1):67–72. doi: 10.1016/s0163-4453(89)93717-1. [DOI] [PubMed] [Google Scholar]
  13. Morse G. D., Shelton M. J., O'Donnell A. M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet. 1993 Feb;24(2):101–123. doi: 10.2165/00003088-199324020-00002. [DOI] [PubMed] [Google Scholar]
  14. Pachón J., Viciana P., Cisneros J. M., García Pesquera F., Castillo J. R., Cañas E. Estudio farmacocinético de zidovudina en adictos a drogas parenterales con infección por el virus de la inmunodeficiencia humana. Med Clin (Barc) 1993 Jan 16;100(2):46–49. [PubMed] [Google Scholar]
  15. Quinn R. P., Orban B., Tadepalli S. Radioimmunoassay for Retrovir, an anti-human immunodeficiency virus drug. J Immunoassay. 1989;10(2-3):177–189. doi: 10.1080/01971528908053235. [DOI] [PubMed] [Google Scholar]
  16. Resetar A., Minick D., Spector T. Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol. 1991 Jul 15;42(3):559–568. doi: 10.1016/0006-2952(91)90319-z. [DOI] [PubMed] [Google Scholar]
  17. Shumaker R. C. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17(3-4):331–348. doi: 10.3109/03602538608998295. [DOI] [PubMed] [Google Scholar]
  18. Sim S. M., Back D. J., Breckenridge A. M. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol. 1991 Jul;32(1):17–21. doi: 10.1111/j.1365-2125.1991.tb05607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Singlas E., Pioger J. C., Taburet A. M., Colaneri S., Fillastre J. P. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients. Eur J Clin Pharmacol. 1989;36(6):639–640. doi: 10.1007/BF00637752. [DOI] [PubMed] [Google Scholar]
  20. St Clair M. H., Richards C. A., Spector T., Weinhold K. J., Miller W. H., Langlois A. J., Furman P. A. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 1987 Dec;31(12):1972–1977. doi: 10.1128/aac.31.12.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES